Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics) Catalyst: Invited six-month ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

Genentech is planning cuts on the Peninsula.

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.